Glenmark, Sun to Sell Generic Version of Trileptal in US (India)
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals and Sun Pharmaceutical Industries have received approval to market a generic version of Trileptal. The drug, also known as oxcarbazepine, is an epilepsy treatment manufactured by Novartis. Last year, Novartis saw about $643 million in sales from the drug, just in the U.S. Glenmark and Sun Pharma, two of India's biggest drug manufacturers, will share the exclusive marketing rights for the generic Trileptal for 180-days. However, they may have to end up sharing the rights during this time with U.S.-based generics company Roxane Laboratories. (Click here for more